A Randomized, Double-blind, Phase 3 Study of Vorasidenib Versus Placebo in Patients with Mutant IDH1/2 Diffuse Glioma (INDIGO): Analysis of Health-related Quality of Life, Neurocognition and Seizures

Author:Peters, Katherine   Mellinghoff, Ingo   Van Den Bent, Martin   Blumenthal, Deborah   Touat, Mehdi   Clarke, Jennifer   Mendez, Joe   Yust-Katz, Shlomit   Mason, Warren   Ducray, Francois   Umemura, Yoshie   Nabors, Burt   Holdhoff, Matthias   Hottinger, Andreas   Arakawa, Yoshiki   Sepúlveda, Juan   Wick, Wolfgang   Soffietti, Riccardo   Perry, James   Giglio, Pierre   De La Fuente, Macarena   Maher, Elizabeth   Bottomley, Andrew   Zhao, Dan   Pandya, Shuchi   Hassan, Islam   Steelman, Lori   Wen, Patrick   Cloughesy, Timothy   

Session Name:PL5: Clinical Trials Plenary Session  

Topic:Neuro-oncology  

Program Number:PL5.003  

Author Institution:Duke University Medical Center, Durham, NC  Memorial Sloan Kettering Cancer Center, New York, NY  Erasmus Medical Center, Rotterdam, Netherlands  Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel  Pitié Salpêtrière Hospital, Assistance Publique-Hôpitaux de Paris (AP-HP), Sorbonne Université, Paris, France  University of California San Francisco, San Francisco, CA  Huntsman Cancer Institute at the University of Utah, Salt Lake City, UT  Davidoff Cancer Center at Rabin Medical Center, Petah Tikva, Israel  Toronto General Hospital, Toronto, ON, Canada  Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Centre de Recherche en Cancérologie de Lyon, Lyon, France  University of Michigan Comprehensive Cancer Center, Ann Arbor, MI  University of Alabama at Birmingham, Birmingham, AL  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD  University Hospital of Lausanne, Lausanne, Switzerland  Kyoto University Graduate School of Medicine, Kyoto, Japan  Hospital Universitario 12 de Octubre, Madrid, Spain  Universitätsklinikum Heidelberg, Heidelberg, Germany  University of Turin, Turin, Italy  Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON, Canada  The Ohio State University Wexner Medical Center, Columbus, OH  Sylvester Comprehensive Cancer Center and Department of Neurology, University of Miami, Miami, FL  University of Texas Southwestern Medical Center, Dallas, TX  Bottomley Consultants, Overijse, Belgium  Servier Pharmaceuticals, Boston, MA  Dana-Farber Cancer Institute, Boston, MA  University of California Los Angeles, Los Angeles, CA  

Clinical Characteristics and Treatment Approaches for H3K27-altered Diffuse Midline Glioma in Adolescents and Young Adults

Discrepancy in CSF Flow Cytometry Results from Lumbar Puncture and Ventricular Sampling Leading to Delay in Diagnosis Recurrent CNS Lymphoma: A Case Report